INDV
Indivior Pharmaceuticals, Inc.
35.80$
-0.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1,438.1% | – | – | -97.7% | -350.0% | – | +110.7% | -124.7% | – | – | – | – | |
| – | +28.6% | -44.4% | +20.0% | +33.3% | -37.5% | +0.0% | +0.0% | +0.0% | +0.0% | -20.0% | -25.0% | – | |
| – | +20.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +33.3% | -12.5% | -28.6% | +80.0% | +22.2% | – | |
| – | -276.0% | – | – | -120.0% | – | – | +572.2% | -180.2% | – | – | – | – | |
| – | -35.7% | -83.3% | +33.3% | +75.0% | +128.6% | -68.8% | +260.0% | +11.1% | +20.0% | -16.7% | -65.0% | – | |
| – | – | +316.7% | -96.0% | +3,400.0% | -71.4% | -150.0% | +240.0% | +17.6% | +20.0% | -20.8% | -57.9% | – | |
| – | +45,410.0% | +63.6% | -2.8% | +45.7% | +0.0% | -78.4% | -97.0% | – | +344.5% | -66,169.6% | +39.7% | – | |
| – | – | – | – | – | – | -104.3% | +0.0% | +0.0% | +25.0% | – | -100.0% | – | |
| – | +2,000.0% | +166.7% | -37.5% | +45.7% | – | -163.0% | -70.6% | -40.0% | +66.7% | – | -2,571.4% | – | |
| – | -1,733.3% | – | – | -125.9% | – | +71.0% | +158.5% | -146.7% | – | – | – | – | |
| – | – | – | – | -106.0% | – | – | +100.0% | -142.1% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.